AD is a growing market with an impressive pipeline of new products from current and future players in the field.

The visible symptoms only scratch the surface of this chronic skin condition Living with a chronic condition like atopic ...

Significant research has documented the impact of atopic dermatitis on mental health. Not only does stress trigger eczema ...

Tralokinumab use in patients with head and neck atopic dermatitis was associated with sustained improvements with up to 4 years of treatment.

Dupilumab in atopic dermatitis treatment had the most favorable cardiometabolic safety profile when compared with methotrexate and cyclosporine.

Responses to dupilumab (Dupixent) treatment were consistent across racial and ethnic groups in children with atopic ...

The atopic dermatitis (AD) treatment landscape is witnessing intensified competition with several novel therapies nearing market entry. While biologics like dupilumab have already transformed care, ...

A new study published in the Journal of European Academy of Dermatology and Venerology showed that compared to patients on ...

Over 10% of people in the United States have some form of eczema and nearly one-fifth experience more than one eczema ...

With the recent developments in the atopic dermatitis (AD) market, the field is becoming more competitive as novel therapies are soon anticipated to enter the market. This evolution may benefit AD ...